Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
77 studies found for:    vaccine niaid | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL Baxter) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
Conditions: Tick-Borne Encephalitis;   Encephalitis, Tick-Borne;   Tick-Borne Disease;   Glycoprotein E, Flavivirus;   NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
2 Recruiting Therapeutic Vaccine for HIV
Conditions: HIV;   Therapeutic Vaccine
Interventions: Biological: rVSV;   Biological: IL-12 pDNA adjuvant;   Biological: HIV-Mag pDNA
3 Recruiting Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Condition: Healthy Volunteers
Intervention:
4 Recruiting Screening Volunteers for Clinical Trials
Condition: Human Volunteers
Intervention:
5 Recruiting Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults
Condition: Ebola Viruses
Interventions: Other: Placebo;   Biological: BPSC1001
6 Recruiting Volunteer Screening for Vaccine and Antivirals Clinical Trials
Condition: Healthy Volunteer
Intervention:
7 Recruiting Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults
Condition: Malaria
Intervention: Biological: PfSPZ Vaccine
8 Recruiting Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Conditions: Genital Herpes;   Herpes Simplex Virus;   Herpes Simplex Virus Vaccines;   HSV Vaccines;   Herpesvirus Vaccines
Intervention: Biological: HSV529
9 Recruiting Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults
Condition: Healthy Adult Immune Responses to Vaccine
Interventions: Biological: VRC-EBOADC069-00-VP;   Biological: VRC-EBOADC076-00-VP
10 Recruiting Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
Condition: H5N1 Influenza
Interventions: Biological: Ad4-H5-VTN vaccination-tonsillar route;   Biological: Ad4-H5-vaccination-oral route
11 Recruiting Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Conditions: Healthy Volunteer;   HIV Vaccine
Interventions: Biological: Ad4-mgag;   Biological: Ad4-EnvC150
12 Recruiting Intranasal AD4-H5-VTN as an Adenovirus Vaccine
Condition: Healthy Volunteer
Intervention: Biological: Ad4-H5-Vtn
13 Recruiting H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...
Condition: Influenza
Interventions: Biological: A/Shanghai/02/2013 (H7N9) MIV;   Biological: VRC-FLUDNA071-00-VP
14 Recruiting Antibody Production in Immune Disorders
Condition: Immunologic Disease
Intervention:
15 Recruiting Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Condition: Blood Component Removal
Intervention:
16 Recruiting VRC 900: Evaluation of Tissue-Specific Immune Responses in Adults 18 Years of Age and Older
Condition: Immune System
Intervention:
17 Recruiting A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
Condition: Pneumococcal Infection
Intervention: Biological: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
18 Recruiting Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine - Admixture TV003;   Biological: TetraVax-DV Vaccine - Admixture TV005;   Biological: Placebo
19 Not yet recruiting A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
Condition: Avian Influenza
Interventions: Drug: MF59;   Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013;   Biological: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca
20 Not yet recruiting Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old
Condition: Influenza A Virus, H7N9 Subtype
Interventions: Biological: H7N9 Anhui 2013/AA ca;   Biological: Inactivated subvirion H7N9 vaccine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years